AU2002218167A1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents
N-phenyl-2-pyrimidine-amine derivativesInfo
- Publication number
- AU2002218167A1 AU2002218167A1 AU2002218167A AU1816702A AU2002218167A1 AU 2002218167 A1 AU2002218167 A1 AU 2002218167A1 AU 2002218167 A AU2002218167 A AU 2002218167A AU 1816702 A AU1816702 A AU 1816702A AU 2002218167 A1 AU2002218167 A1 AU 2002218167A1
- Authority
- AU
- Australia
- Prior art keywords
- pyrimidine
- phenyl
- amine derivatives
- preparation
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0022438 | 2000-09-13 | ||
GBGB0022438.6A GB0022438D0 (en) | 2000-09-13 | 2000-09-13 | Organic Compounds |
PCT/EP2001/010503 WO2002022597A1 (en) | 2000-09-13 | 2001-09-11 | N-phenyl-2-pyrimidine-amine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002218167A1 true AU2002218167A1 (en) | 2002-03-26 |
Family
ID=9899367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002218167A Abandoned AU2002218167A1 (en) | 2000-09-13 | 2001-09-11 | N-phenyl-2-pyrimidine-amine derivatives |
Country Status (14)
Country | Link |
---|---|
US (3) | US7081532B2 (de) |
EP (1) | EP1322634B1 (de) |
JP (1) | JP2004509111A (de) |
CN (2) | CN1872850A (de) |
AT (1) | ATE452129T1 (de) |
AU (1) | AU2002218167A1 (de) |
BR (1) | BR0113838A (de) |
CA (2) | CA2416274C (de) |
DE (1) | DE60140814D1 (de) |
ES (1) | ES2336891T3 (de) |
GB (1) | GB0022438D0 (de) |
HK (1) | HK1057752A1 (de) |
PT (1) | PT1322634E (de) |
WO (1) | WO2002022597A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
EP1408978A4 (de) * | 2001-06-21 | 2005-07-13 | Ariad Pharma Inc | Neue phenylamino-pyrimidine und ihre verwendungszwecke |
GB0201508D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
RU2315043C2 (ru) * | 2002-06-28 | 2008-01-20 | Ниппон Синяку Ко., Лтд. | Амидное производное, фармацевтическая композиция и терапевтические средства на его основе |
AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
CA2439440A1 (en) | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
AU2003273675A1 (en) * | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
WO2004099186A1 (en) * | 2003-05-06 | 2004-11-18 | Il Yang Pharm Co., Ltd. | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
WO2004108699A1 (en) * | 2003-06-06 | 2004-12-16 | Natco Pharma Limited | Process for the preparation of the anti-cancer drug imatinib and its analogues |
ES2338557T3 (es) * | 2003-06-13 | 2010-05-10 | Novartis Ag | Derivados de la 2-aminopirimidina utilizados como inhibidores de la raf cinasa. |
JPWO2005063720A1 (ja) * | 2003-12-25 | 2007-07-19 | 日本新薬株式会社 | アミド誘導体及び医薬 |
KR100848067B1 (ko) | 2003-12-25 | 2008-07-23 | 니뽄 신야쿠 가부시키가이샤 | 아미드 유도체 및 의약 |
AR047530A1 (es) | 2004-02-04 | 2006-01-25 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida |
WO2006017353A2 (en) * | 2004-07-13 | 2006-02-16 | GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of viral infections |
CA2591321C (en) | 2004-09-09 | 2013-09-24 | Natco Pharma Limited | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
US7939541B2 (en) | 2004-09-09 | 2011-05-10 | Natco Pharma Limited | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
CN1939910A (zh) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
CN1972917B (zh) * | 2004-12-31 | 2010-08-25 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
DE602006015994D1 (de) * | 2005-06-23 | 2010-09-16 | Novartis Ag | Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
NZ566862A (en) * | 2005-09-27 | 2010-12-24 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors |
US8067421B2 (en) * | 2006-04-27 | 2011-11-29 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
US20090324718A1 (en) * | 2006-09-01 | 2009-12-31 | Ilan Zalit | Imatinib compositions |
EP2364702A3 (de) * | 2006-09-05 | 2012-01-25 | Emory University | Tyrosinkinasehemmer zur Vorbeugung oder Behandlung von Infektionen |
EP2009008A1 (de) | 2006-10-26 | 2008-12-31 | Sicor, Inc. | Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür |
US20080103305A1 (en) * | 2006-10-26 | 2008-05-01 | Macdonald Peter | Process for the preparation of imatinib |
EP2121681B1 (de) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Verbindungen und verfahren zur behandlung von krebs |
MX2009011950A (es) | 2007-05-04 | 2009-12-11 | Irm Llc | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. |
US20090012296A1 (en) * | 2007-05-29 | 2009-01-08 | Alexandr Jegorov | Processes for the preparation of crystalline form beta of imatinib mesylate |
EP2152079A4 (de) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Heterocyclische verbindungen und ihre verwendung |
BRPI0815715A8 (pt) | 2007-08-22 | 2017-07-04 | Irm Llc | Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases. |
ES2368876T3 (es) | 2007-08-22 | 2011-11-23 | Irm Llc | Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa. |
KR101041203B1 (ko) * | 2007-09-25 | 2011-06-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 이매티닙 조성물 |
EP2225226B1 (de) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Verbindungen und ihre verwending in einem verfahren zur behandlung von krebs |
CA2713288A1 (en) * | 2008-02-11 | 2009-08-20 | The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services | Compounds with mdr1-inverse activity |
PT2265607T (pt) | 2008-02-15 | 2017-03-08 | Rigel Pharmaceuticals Inc | Compostos de pirimidina-2-amina e sua utilização como inibidores de jak cinases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
LT2300013T (lt) | 2008-05-21 | 2017-12-27 | Ariad Pharmaceuticals, Inc. | Fosforo dariniai kaip kinazių inhibitoriai |
JP2011526292A (ja) * | 2008-06-27 | 2011-10-06 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 神経線維腫および関連する腫瘍を抑制および/または治療する物質および方法 |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
CN101417995B (zh) * | 2008-11-21 | 2012-06-06 | 陈依军 | 苯氧基嘧啶衍生物及其制备方法和用途 |
CN102459252A (zh) | 2009-04-15 | 2012-05-16 | 阿斯利康(瑞典)有限公司 | 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶 |
US8530492B2 (en) * | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
WO2010120388A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2552915B1 (de) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Verbindungen zur behandlung von hiv |
CN102212057B (zh) * | 2011-04-13 | 2013-11-27 | 合肥工业大学 | 一种羧酸类非甾体抗炎药衍生物及其制备方法和用途 |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
CN102796110B (zh) * | 2011-05-23 | 2016-03-30 | 复旦大学 | 苯胺嘧啶化合物及其制备方法和用途 |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CN103044394A (zh) * | 2012-12-20 | 2013-04-17 | 北京理工大学 | 一种苯基氨基嘧啶衍生物及其制备方法和用途 |
CN103058935B (zh) * | 2013-01-15 | 2015-05-06 | 四川大学 | 一种嘧啶类化合物及其制备方法和用途 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN105859683B (zh) * | 2016-04-11 | 2018-09-28 | 连云港恒运药业有限公司 | 伊马替尼的高纯度工业制备工艺 |
CN107805240A (zh) * | 2016-09-08 | 2018-03-16 | 中国科学院合肥物质科学研究院 | 一种新型的pdgfr激酶抑制剂及其用途 |
CN107652266A (zh) * | 2017-10-27 | 2018-02-02 | 上海应用技术大学 | 一种靶向酪氨酸激酶小分子抑制剂及其应用 |
CN114127065A (zh) * | 2019-03-05 | 2022-03-01 | 鸿仪有限责任公司 | 用于治疗神经退行性疾病和癌症的化合物 |
CN110078708B (zh) * | 2019-05-08 | 2020-12-11 | 东南大学 | Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
-
2000
- 2000-09-13 GB GBGB0022438.6A patent/GB0022438D0/en not_active Ceased
-
2001
- 2001-09-11 AT AT01984640T patent/ATE452129T1/de active
- 2001-09-11 CN CNA2006101002584A patent/CN1872850A/zh active Pending
- 2001-09-11 CA CA2416274A patent/CA2416274C/en not_active Expired - Fee Related
- 2001-09-11 DE DE60140814T patent/DE60140814D1/de not_active Expired - Lifetime
- 2001-09-11 EP EP01984640A patent/EP1322634B1/de not_active Expired - Lifetime
- 2001-09-11 BR BR0113838-3A patent/BR0113838A/pt not_active IP Right Cessation
- 2001-09-11 JP JP2002526850A patent/JP2004509111A/ja active Pending
- 2001-09-11 CN CNB018155391A patent/CN100406452C/zh not_active Expired - Fee Related
- 2001-09-11 ES ES01984640T patent/ES2336891T3/es not_active Expired - Lifetime
- 2001-09-11 US US10/363,841 patent/US7081532B2/en not_active Expired - Lifetime
- 2001-09-11 CA CA2687476A patent/CA2687476A1/en not_active Abandoned
- 2001-09-11 AU AU2002218167A patent/AU2002218167A1/en not_active Abandoned
- 2001-09-11 PT PT01984640T patent/PT1322634E/pt unknown
- 2001-09-11 WO PCT/EP2001/010503 patent/WO2002022597A1/en active Application Filing
-
2003
- 2003-11-26 HK HK03108645A patent/HK1057752A1/xx not_active IP Right Cessation
-
2006
- 2006-06-07 US US11/448,649 patent/US7312216B2/en not_active Expired - Fee Related
-
2007
- 2007-07-26 US US11/828,367 patent/US7329661B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2416274A1 (en) | 2002-03-21 |
CN100406452C (zh) | 2008-07-30 |
ES2336891T3 (es) | 2010-04-19 |
BR0113838A (pt) | 2003-06-03 |
EP1322634B1 (de) | 2009-12-16 |
DE60140814D1 (de) | 2010-01-28 |
US7081532B2 (en) | 2006-07-25 |
CA2687476A1 (en) | 2002-03-21 |
CN1525967A (zh) | 2004-09-01 |
US20070265292A1 (en) | 2007-11-15 |
EP1322634A1 (de) | 2003-07-02 |
US7329661B2 (en) | 2008-02-12 |
US20060223818A1 (en) | 2006-10-05 |
US20040102453A1 (en) | 2004-05-27 |
GB0022438D0 (en) | 2000-11-01 |
HK1057752A1 (en) | 2004-04-16 |
JP2004509111A (ja) | 2004-03-25 |
PT1322634E (pt) | 2010-02-22 |
US7312216B2 (en) | 2007-12-25 |
WO2002022597A1 (en) | 2002-03-21 |
CN1872850A (zh) | 2006-12-06 |
CA2416274C (en) | 2011-01-04 |
ATE452129T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002218167A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
HK1065483A1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
MY139303A (en) | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
MY137039A (en) | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | |
WO2004060882A8 (en) | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | |
ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
MXPA04000577A (es) | Derivados de dolastatina 10. | |
EP1783126A3 (de) | N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten | |
TW200510392A (en) | Chemical compounds | |
TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
TW200505452A (en) | Chemical compounds | |
UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
DE60001586D1 (de) | Diphenyl-piperidin derivate | |
TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
AU2001266019A1 (en) | 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives | |
TW200504051A (en) | Novel acridine derivatives and their use as medicaments | |
MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
WO2004108094A3 (en) | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | |
ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
EP1232748A4 (de) | Subsituierte nitrobenzol derivate mit medikamentöser oder anderer wirkung | |
AU2003298203A1 (en) | Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles |